Hormone replacement therapy

The number of women who will live half their adult lives after the menopause increases every year.1 A challenging question for doctors is how women should be counselled about postmenopausal oestrogen therapy. #### Summary points Five or more years of postmenopausal oestrogen is the standard of care for the prevention or treatment of osteoporosis; benefit requires continued use Oestrogen increases the risk of endometrial cancer during and after use,unless it is taken with adequate progestogen It probably increases the risk of breast cancer, but only during current use It may reduce the risk of coronary heart disease Routine oestrogen treatment should not be recommended until more risk:benefit data are available from clinical trials This review is based on observations during 25 years of research into women's health, and on Medline searches on oestrogen or menopause. Only recent publications are cited. Unless otherwise stated, oestrogen therapy refers to treatment of postmenopausal women with pharmacological doses of oral oestrogen taken alone or with an oral progestogen. About 75% of women in English speaking countries experience no troublesome symptoms during the menopause transition.2 Population studies have shown that symptoms are less common or different in other countries, and more common and more severe after an induced menopause. Hot flushes and night sweats are the only symptoms universally reported to respond (usually almost immediately) to oestrogen. Without treatment, hot flushes typically disappear within 1-2 years, but in some untreated women they continue for more than 20 years. After the menopause the vaginal wall becomes thinner and less vascular, changes which may be accompanied by vaginal dryness and dyspareunia. Intravaginal oestrogen prevents and treats these symptoms and also reduces the risk of recurrent urinary tract infection, probably by modifying the vaginal flora.3 Urinary incontinence, which becomes more common with increasing age, is not usually improved …

[1]  M. Pike,et al.  Estrogen-progestin replacement therapy and endometrial cancer. , 1998, Journal of the National Cancer Institute.

[2]  Research on the menopause in the 1990s. Report of a WHO Scientific Group. , 1996, World Health Organization technical report series.

[3]  G. Penney,et al.  A population based survey of women's experience of the menopause , 1996, British journal of obstetrics and gynaecology.

[4]  E. Barrett-Connor,et al.  Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. , 1997, JAMA.

[5]  Svend Kreiner,et al.  Hormone replacement therapy and risk of non-fatal stroke , 1997, The Lancet.

[6]  S. Cummings,et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.

[7]  Ján,et al.  Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1995, JAMA.

[8]  A. LaCroix,et al.  Estrogen replacement therapy and prognosis after first myocardial infarction. , 1997, American journal of epidemiology.

[9]  J A Kanis,et al.  Estrogens, the menopause, and osteoporosis. , 1996, Bone.

[10]  H. Genant,et al.  Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels , 1997 .

[11]  A. Miller,et al.  Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.

[12]  D. Torgerson,et al.  Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. , 1997, Archives of internal medicine.

[13]  S B Hulley,et al.  Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. , 1998, Controlled clinical trials.

[14]  C. Joyce,et al.  Quality of life after the menopause: influence of hormonal replacement therapy. , 1994, American journal of obstetrics and gynecology.

[15]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[16]  B. Rosner,et al.  Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. , 1992, The New England journal of medicine.

[17]  H. Newnham,et al.  Coronary heart disease. Women's hearts are hard to break. , 1997, Lancet.

[18]  S. Sidney,et al.  Increased risk of cholecystectomy in users of supplemental estrogen. , 1988, Gastroenterology.

[19]  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. , 1996, JAMA.

[20]  A. Lane,et al.  Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.

[21]  L. Kuller,et al.  Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. , 1997, Archives of internal medicine.

[22]  H. Genant,et al.  LOW-DOSE ESTERIFIED ESTROGEN THERAPY : EFFECTS ON BONE, PLASMA ESTRADIOL CONCENTRATIONS, ENDOMETRIUM, AND LIPID LEVELS , 1998 .

[23]  R. Califf,et al.  Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. , 1996, Journal of the American College of Cardiology.

[24]  C. Furberg,et al.  Venous thromboembolic events associated with hormone replacement therapy. , 1997, JAMA.

[25]  H. Genant,et al.  The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. , 1996, JAMA.

[26]  H. Newnham,et al.  Women's hearts are hard to break , 1997, The Lancet.

[27]  R. Lindsay,et al.  Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. , 1998, The American journal of clinical nutrition.

[28]  D. McClish,et al.  Estrogen Therapy in the Management of Urinary Incontinence in Postmenopausal Women: A Meta-Analysis. First Report of the Hormones and Urogenital Therapy Committee , 1994, Obstetrics and gynecology.

[29]  H. Tunstall-Pedoe Myth and paradox of coronary risk and the menopause , 1998, The Lancet.

[30]  P. Newcomb,et al.  Postmenopausal hormone use and risk of large-bowel cancer. , 1995, Journal of the National Cancer Institute.

[31]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[32]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[33]  R. Westendorp,et al.  Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? , 1994, BMJ.

[34]  N. Weiss,et al.  Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women , 1997, The Lancet.

[35]  A. Paganini-Hill Estrogen replacement therapy and stroke. , 1995, Progress in cardiovascular diseases.

[36]  H. Genant,et al.  Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. , 1987, Annals of internal medicine.

[37]  W. Stamm,et al.  A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. , 1993, The New England journal of medicine.

[38]  K. McPherson,et al.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials , 1997, BMJ.

[39]  S. Taplin,et al.  Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. , 1996, Journal of the National Cancer Institute.

[40]  L. Speroff,et al.  The heart and estrogen/progestin replacement study (HERS). , 1998, Maturitas.

[41]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[42]  N. Wintfeld,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[43]  H. Genant,et al.  Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. , 1997, Archives of internal medicine.